Olema PharmaceuticalsOLMA +2.60%33 PB Ratio is 2.08 as of Jun. 26, 2026. GuruFocus rates OLMA with a GF Score™ of 33/100. The stock has 2 warning signs investors should review. Among 1,232 Biotechnology companies, Olema Pharmaceuticals ranks better than 60.88% on this metric.
The historical rank and industry rank for Olema Pharmaceuticals's PB Ratio or its related term are showing as below:
OLMA'
s PB Ratio Range Over the Past 10 Years
Min: 0 Med: 0 Max: 2.14
Current: 2.08
During the past 8 years, Olema Pharmaceuticals's highest PB Ratio was 2.14. The lowest was 0.00. And the median was 0.00.
OLMA's PB Ratio is ranked better than 60.88% of 1232
companies
in the Biotechnology industry
Industry Median: 2.8
vs OLMA: 2.08
During the past 12 months, Olema Pharmaceuticals's average Book Value Per Share Growth Rate was 6.90% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 6.30% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -7.60% per year.
During the past 8 years, the highest 3-Year average Book Value Per Share Growth Rate of Olema Pharmaceuticals was 6.30% per year. The lowest was -18.70% per year. And the median was -8.40% per year.
Back to Basics: PB Ratio
Olema Pharmaceuticals (NAS:OLMA) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Olema Pharmaceuticals's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Olema Pharmaceuticals PB Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Olema Pharmaceuticals's PB Ratio distribution charts can be found below:
* The bar in red indicates where Olema Pharmaceuticals's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Olema Pharmaceuticals (OLMA) has a PB Ratio of 2.08 as of Jun. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Olema Pharmaceuticals and its competitors. According to the industry distribution chart, Olema Pharmaceuticals ranks #482 out of 1232 companies in the Biotechnology industry, placing it in the top 39.1%.
Is Olema Pharmaceuticals' PB Ratio too high?
Olema Pharmaceuticals' current PB Ratio is 2.08. The Biotechnology industry median PB Ratio is 2.80. Olema Pharmaceuticals' value of 2.08 is 25.7% below this industry median. Based on the distribution chart, Olema Pharmaceuticals ranks #482 out of 1232 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Olema Pharmaceuticals has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Olema Pharmaceuticals' PB Ratio compare to AKTS and ZBIO?
According to the Biotechnology industry distribution chart, Olema Pharmaceuticals ranks #482 out of 1232 companies for PB Ratio. This puts Olema Pharmaceuticals in the upper half of its industry. The industry median PB Ratio is 2.80. Olema Pharmaceuticals' value of 2.08 is 25.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Biotechnology company?
The median PB Ratio among Biotechnology companies is 2.80, based on 1,232 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Olema Pharmaceuticals's current PB Ratio of 2.08 is 25.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Olema Pharmaceuticals and its competitors. For the Biotechnology industry, the median PB Ratio is 2.80 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Olema Pharmaceuticals's current PB Ratio is 2.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Olema Pharmaceuticals stock overvalued right now?
Olema Pharmaceuticals (OLMA) has a current PB Ratio of 2.08. The current PB Ratio is 2.08 and 25.7% below the Biotechnology industry median of 2.80. Olema Pharmaceuticals' overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Olema Pharmaceuticals (OLMA), the current PB Ratio is 2.08 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Olema Pharmaceuticals inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of next generation targeted therapies for women's cancers. Its therapies offer the potential to improve outcomes for women living with cancer. The company has completed discovery and preclinical studies of OP-1250. OP-3136 is another drug candidate in the company's product pipeline.
33GF Score
Get the complete analysis for OLMA
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OLMA has been successfully added to your 
